Folic acid and methylenetetrahydrofolate reductase (MTHFR) may affect the development of human cancer. However, few studies have evaluated folate intake and MTHFR in susceptibility to and prognosis of patients with ovarian cancer. We conducted a prospective case-control study in 215 ovarian cancer patients and 218 controls (all Chinese) between Jan. 2004 and Jan. 2007. MTHFR C677T genotyping was done by PCR-RFLP. All patients were followed up until Dec. 2010. We found a 2.43-fold increased risk of ovarian cancer among MTHFR 677TT carriers, and a decreased risk of ovarian cancer in individuals with high folate intake (OR = 0.54, 95% CI = 0.32–0.94). Cox regression survival analysis showed that among the ovarian cancer patients, those carrying the 677TT genotype had a higher risk of death (HR = 2.17, 95% CI = 1.20–4.79), while high folate intake was associated with a lower risk of death (HR = 0.43, 95% CI = 0.33–0.88). Moreover, MTHFR 677CC carriers with higher folate intake showed a lower risk of death from ovarian cancer (HR = 0.32, 95% CI = 0.27–0.82). In summary, high folate intake may lessen susceptibility and improve the prognosis of ovarian cancer patients, while the MTHFR 677TT genotype appears to increase ovarian cancer risk and worsen its prognosis in a Chinese population.
Jin, F.; Shu, X.O.; Devesa, S.S.; Zheng, W.; Blot, W.J.; Gao, Y.T. Incidence trends for cancers of the breast, ovary, and corpus uteri in urban Shanghai, 1972–89. Cancer Causes Control 1993, 4, 355–360.
[3]
La Vecchia, C. Epidemiology of ovarian cancer: A summary review. Eur. J. Cancer Prev 2001, 10, 125–129.
[4]
Zhang, M.; Xie, X.; Lee, A.H.; Binns, C.W. Soy and isoflavone intake are associated with reduced risk of ovarian cancer in southeast China. Nutr. Cancer 2004, 49, 125–130.
[5]
Aune, D.; Deneo-Pellegrini, H.; Ronco, A.L.; Boffetta, P.; Acosta, G.; Mendilaharsu, M.; de Stefani, E. Dietary folate intake and the risk of 11 types of cancer: A case-control study in Uruguay. Ann. Oncol 2010, 22, 444–451.
[6]
Kim, Y.I. Will mandatory folic acid fortification prevent or promote cancer? Am. J. Clin. Nutr 2004, 80, 1123–1128.
[7]
Larsson, S.C.; Giovannucci, E.; Wolk, A. Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: A meta-analysis. Gastroenterology 2006, 131, 1271–1283.
[8]
Choi, S.W.; Mason, J.B. Folate and carcinogenesis: An integrated scheme. J. Nutr 2000, 13, 129–132.
[9]
Gallus, S.; La Vecchia, C. Is there a link between diet and esophageal cancer? Nat. Clin. Pract. Gastroenterol. Hepatol 2007, 4, 2–3.
[10]
Blount, B.C.; Mack, M.M.; Wehr, C.M.; MacGregor, J.T.; Hiatt, R.A.; Wang, G. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: Implications for cancer and neuronal damage. Proc. Natl. Acad. Sci. USA 2007, 94, 3290–3295.
[11]
Bailey, L.B.; Gregory, J.F., 3rd. Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: Metabolic significance, risks and impact on folate requirement. J. Nutr. 1999, 129, 919–922.
[12]
Frosst, P.; Blom, H.J.; Milos, R.; Goyette, P.; Sheppard, C.A.; Matthews, R.G.; Boers, G.J.; den Heijer, M.; Kluijtmans, L.A.; van den Heuvel, L.P.; et al. A candidate genetic risk factor for vascular disease: A commonmutation inmethylenetetrahydrofolate reductase. Nat. Genet 1995, 10, 111–113.
Upadhyay, R.; Jain, M.; Kumar, S.; Ghoshal, U.C.; Mittal, B. Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for esophageal squamous cell carcinoma. Mutat. Res 2009, 663, 52–59.
[15]
Upadhyay, R.; Jain, M.; Kumar, S.; Ghoshal, U.C.; Mittal, B. Association of interleukin-6 (？174G>C) promoter polymorphism with risk of squamous cell esophageal cancer and tumor location: An exploratory study. Clin. Immunol 2008, 128, 199–204.
[16]
Jain, M.; Tilak, A.R.; Upadhyay, R.; Kumar, A.; Mittal, B. Microsomal epoxide hydrolase (EPHX1), slow (exon 3, 113His) and fast (exon 4, 139Arg) alleles confer susceptibility to squamous cell esophageal cancer. Toxicol. Appl. Pharmacol 2008, 230, 247–251.
[17]
Wang, J.; Sasco, A.J.; Fu, C.; Xue, H.; Guo, G.; Hua, Z.; Zhou, Q.; Jiang, Q.; Xu, B. Aberrant DNA methylation of P16, MGMT, and hMLH1 genes in combination with MTHFR C677T genetic polymorphism in esophageal squamous cell carcinoma. Cancer Epidemiol. Biomark. Prev 2008, 17, 118–125.
[18]
Mason, J.B. Folate, cancer risk, and the Greek god, Proteus: A tale of two chameleons. Nutr. Rev 2009, 67, 206–212.
[19]
Webb, P.M.; Ibiebele, T.I.; Hughes, M.C.; Beesley, J.; van der Pols, J.C.; Chen, X.; Nagle, CM.; Bain, C.J.; Chenevix-Trench, G. Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group. Folate and related micronutrients, folate-metabolising genes and risk of ovarian cancer. Eur. J. Clin. Nutr 2011, 65, 1133–1140.
[20]
Harris, H.R.; Cramer, D.W.; Vitonis, A.F.; Depari, M.; Terry, K.L. Folate, vitamin B(6), vitamin B(12), methionine and alcohol intake in relation to ovarian cancer risk. Int. J. Cancer 2011, 22, doi:10.1002/ijc.26455.
[21]
Ito, H.; Shinoda, M.; Hatooka, S.; Hirose, K.; Wakai, K.; Saito, T.; Wakai, K.; Saito, T.; Suzuki, T.; Maeda, T.; et al. Gene-environment interactions between alcohol drinking and the MTHFR C677T polymorphism impact on esophageal cancer risk: Results of a case-control study in Japan. Carcinogenesis 2005, 26, 1285–1290.
[22]
Wang, Y.; Guo, W.; He, Y.; Chen, Z.; Wen, D.; Zhang, X.; Wang, N.; Li, Y.; Ge, H.; Zhang, J. Association of MTHFR C677T and SHMT(1) C1420T with susceptibility to ESCC and GCA in a high incident region of Northern China. Cancer Causes Control 2007, 18, 143–152.
[23]
Goode, E.L.; Maurer, M.J.; Sellers, T.A.; Phelan, C.M.; Kalli, K.R.; Fridley, B.L.; Vierkant, R.A.; Armasu, S.M.; White, K.L.; Keeney, G.L.; et al. Inherited determinants of ovarian cancer survival. Clin. Cancer Res 2010, 16, 995–1007.
[24]
Jakubowska, A.; Gronwald, J.; Menkiszak, J.; Górski, B.; Huzarski, T.; Byrski, T.; Edler, L.; Lubiński, J.; Scott, R.J.; Hamann, U. Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks. Breast Cancer Res. Treat 2007, 104, 299–308.
Carlsson, G.; Hafstr？m, L.O.; Spears, C.P.; Gustavsson, B.; Larsson, P.A. 5-fluorouracil (5-FU) and 5, 10-methylene tetrahydrofolate (5, 10-CH2FH4) as adjuvant therapy in an experimental rodent colon carcinoma model. Anticancer Res 1997, 17, 3671–3674.
[27]
Cohen, V.; Panet-Raymond, V.; Sabbaghian, N.; Morin, I.; Batist, G.; Rozen, R. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: A novel genomic predictor of clinical response to fluoropyrimidinebased chemotherapy. Clin. Cancer Res 2003, 9, 1611–1615.
[28]
Lu, C.; Xie, H.; Wang, F.L.; Shen, H.B.; Wang, J.M. Diet folate, DNA methylation and genetic polymorphisms of MTHFR C677T in association in the prognosis of esophageal squamous cell carcinoma. BMC Cancer 2011, 11, doi:10.1186/1471-2407-11-91.
[29]
Sarbia, M.; Stahl, M.; von Weyhern, C.; Weirich, G.; Pühringer-Oppermann, F. The prognostic significance of genetic polymorphisms (methylenetetrahydrofolate reductase C677T, methionine synthase A2756G, thymidilate synthase tandem repeat polymorphism) in multimodally treated oesophageal squamous cell carcinoma. Br. J. Cancer 2006, 94, 203–207.
[30]
Hunn, J.; Rodriguez, G.C. Ovarian cancer: Etiology, risk factors, and epidemiology. Clin. Obstet. Gynecol 2012, 55, 3–23.
[31]
Sawabe, M.; Arai, T.; Araki, A.; Hosoi, T.; Kuchiba, A.; Tanaka, N.; Naito, T.; Oda, K.; Ikeda, S.; Muramatsu, M. Smoking confers a MTHFR 677C>T genotype-dependent risk for systemic atherosclerosis: Results from a large number of elderly autopsy cases that died in a community-based general geriatric hospital. J. Atheroscler. Thromb 2009, 16, 91–104.
[32]
Tsai, C.W.; Hsu, C.F.; Tsai, M.H.; Tsou, Y.A.; Hua, C.H.; Chang, W.S.; Lin, C.C.; Bau, D.T. Methylenetetrahydrofolate reductase (MTHFR) genotype, smoking habit, metastasis and oral cancer in Taiwan. Anticancer Res 2011, 31, 2395–2399.
[33]
Supic, G.; Jovic, N.; Kozomara, R.; Zeljic, K.; Magic, Z. Interaction between the MTHFR C677T polymorphism and alcohol—impact on oral cancer risk and multiple DNA methylation of tumor-related genes. J. Dent. Res 2011, 90, 65–70.
